The invention provides, in part, novel SV-BR cancer cell lines. The invention provides a novel cell line SV-BR-1 deposited under ATCC PTA-1712 and SV-BR-1-GM cells deposited under ATCC PTA-1713. The invention further relates to therapeutic and non-therapeutic uses of the novel cell lines. Therapeutic uses include the use of SV-BR cell lines as cancer vaccines, and in particular, or the treatment of cancer.